Thursday, July 9, 2026

Universal Health Organisation (UHO) Weekly Newsletter – 18 July 2025

Date:

Highlights:
  • Gene-based injections, genetically modified foods & inhalation of mRNA-based medications & vaccines: Caution and more research needed
  • Gene-edited rice
  • In the pipeline: inhalable mRNA medicines and vaccines
  • NIMHANS study finds neurological complications associated with COVID-19 vaccines

Download: https://uho.org.in/nl/2025-07-18-newsletter.pdf [copy & paste the link]

Website: https://uho.org.in

Dr. Amitav Banerjee from the Universal Health Organization (UHO) released the latest UHO Newsletter, focusing on the rapidly evolving field of gene technology. The newsletter highlights both the scientific promise of gene-based advancements and significant concerns regarding their swift and widespread application, particularly without comprehensive understanding of long-term adverse effects.

Dr. Banerjee initiated the discussion by acknowledging gene technology as a groundbreaking scientific tool, one that has even earned a Nobel Prize. However, he immediately pivoted to the cautious approach needed for its current applications. “We are surrounded by genes in many ways,” stated Dr. Banerjee, “whether it’s the mRNA vaccines like the COVID vaccines, which, while not termed gene therapy, undeniably use genetic material to instruct the body’s cells.” He emphasized that genes act as messengers to our cells, carrying characteristics within the nucleus’s chromosomes. The concern arises as gene technology is now being used to send messages to our biological systems in diverse ways, from inducing spike protein production to altering grains in our food, necessitating “thorough research” before rapid adoption.

A critical point in the newsletter was the discussion of a recent study from the National Institute of Mental Health and Neurosciences (NIMHANS) in Bengaluru. This research reveals that COVID-19, and notably COVID-19 vaccines, can cause long-term neurological damage and disorders such as Bell’s palsy, Guillain-Barré syndrome, and strokes. “This is significant because it acknowledges that vaccines can have side effects—something that is difficult to accept but important to recognize,” Dr. Banerjee noted. He further highlighted that NIMHANS’ initial studies suggest that the vaccines may cause even more neurological issues than the virus itself, recommending urgent long-term studies.

Dr. Banerjee categorized the pervasive nature of gene technology into three parts: currently used gene-based injections, genetically modified (GMO) foods like rice entering agriculture, and emerging technologies such as “breathable genes,” which could lead to vaccine delivery via nasal sprays or even air-based methods. “We are consuming genetically modified food, receiving gene-based injections, and may even inhale gene-based products. Genetic research is trending everywhere,” he cautioned.

Despite growing concerns, Dr. Banerjee expressed surprise at the recent authorization by the U.S. FDA of the mRNA vaccine 1273 Spikevax for children aged six months to 11 years for the 2025-26 respiratory season. This decision, transitioning from prior Emergency Use Authorization to full authorization, appears paradoxical given the mounting evidence of potential harm. He cited testimony from leading cardiologist Peter McCullough at the US Senate, who reported that autopsy findings indicate 73.9% of sudden deaths in children and young people are due to myocarditis caused by gene-based mRNA vaccines.

The UHO underscores that real change will be gradual, emphasizing that continued public awareness, activism, and legal notices will be crucial for progress in ensuring responsible and safe implementation of gene technology.

Advocacy Group Calls for Urgent Scrutiny of Gene-Based Technologies Amidst Accelerated Nipah Virus Vaccine Development and Relaxed Crop Regulations

A prominent advocacy group today issued a stark warning regarding the accelerating development of mRNA vaccines, particularly for the rare Nipah virus, and the increasing push for genome-edited agricultural products. The group urged immediate and thorough safety assessments, emphasizing that gradual, well-researched changes are essential for public safety, particularly for children.

“Even after reviewing concerning reports, if authorizations for new gene-based technologies are granted, it indicates strong underlying forces at play,” stated a spokesperson for the group. “Significant changes won’t happen overnight; they will be incremental. We must keep pushing, raising awareness, and ensuring legal and public scrutiny to safeguard our future.”

The group expressed deep concern over the trajectory of mRNA vaccine development:

  • Nipah Virus Vaccine Acceleration: Despite the Nipah virus being historically rare and localized, with only sporadic cases annually, significant international funding – including $13.38 million from CEPI to Pune-based Genova Biopharmaceuticals – is fast-tracking an mRNA vaccine. The group questions the urgency, alleging the threat is being exaggerated to justify mass vaccination and commercial gains. They highlighted that Nipah is deadly but affects very few people globally and does not spread widely, suggesting targeted education for at-risk groups is a more proportionate response.
  • mRNA Vaccine Safety Concerns: The group reiterated long-standing concerns about mRNA technology, citing global acknowledgements of cardiac and clotting disorders linked to Covishield (AstraZeneca), a gene-based vaccine. They noted that even Pfizer’s mRNA vaccine was not granted full authorization by the US FDA during the COVID-19 pandemic, raising questions about regulatory rigor when compared to its widespread use elsewhere.
  • The “Pandemic Game Plan”: The group alleges a perceived “game plan” to declare potential pandemics based on isolated cases, enabling the rapid deployment of these vaccines. This strategy, they warn, aligns with ongoing discussions around a global pandemic treaty, potentially centralizing control over public health responses and vaccine mandates. The involvement of cutting-edge AI technology in vaccine development, as seen with Genova and the US-based Houston Methodist Research Institute, further compounds concerns regarding unforeseen outcomes.

Beyond vaccines, the group voiced alarm over the recent announcement by the Indian Council of Agricultural Research (ICAR) regarding the development of genome-edited rice varieties (DRR Dhan 100 Kamla and Pusa DST rice). They critically noted simplified biosafety regulations for these crops, despite warnings from scientists and civil society groups like “GM Free India.”

“Scientists working on genome-edited crops assure safety, but if some scientists express concerns, they should be taken seriously,” the spokesperson added. Noted activist Kavita Kuruganti, an ecology and agriculture scientist, echoed this sentiment, cautioning against rushing the rollout of genome-edited crops without thorough biosafety assessments. Dr. Kritika Yagna, a biotechnologist, emphasized that genome editing using CRISPR technology is far from simple, underscoring the need for meticulous evaluation.

The group calls upon policymakers, regulatory bodies, and the public to demand transparency, robust independent safety testing, and comprehensive public discourse before widespread adoption of these gene-based technologies. They advocate for a ‘slow and steady’ approach, emphasizing education and targeted interventions for genuine threats, rather than mass solutions potentially driven by commercial interests.

“Our children must be protected,” the spokesperson concluded. “Research must continue, but it must be accompanied by unwavering caution and the highest ethical standards, prioritizing public health over profit or convenience.”

About Concerned Citizens for Health & Safety: Concerned Citizens for Health & Safety is an advocacy group dedicated to promoting public awareness, demanding transparency, and advocating for rigorous safety assessments of novel medical and agricultural technologies, with a focus on protecting vulnerable populations, especially children.

Experts Sound Alarm on Unpredictable Gene Technologies and Vaccine Link to Neurological Complications; Call for Rigorous Oversight and Reassessment of GMO Norms

Leading scientists and public health advocates today issued a stark warning regarding the inherent unpredictability and potential risks of advanced gene technologies, including gene editing and certain mRNA applications. During a detailed presentation, Dr. Kritika highlighted concerns about far-reaching genetic, ecological, and neurological consequences, urging immediate re-evaluation of current regulatory frameworks.

Dr. Kritika emphasized that technologies like CRISPR-based genome editing are akin to “mathematical models whose outcomes can vary,” lacking guaranteed predictability. “While seemingly promising, there is no guarantee it will follow the right path or be free of side effects,” she stated, presenting evidence of potential “large-scale genetic damage,” off-target mutations, and the transmission of “wrong messages” within biological systems, drawing an analogy to miscommunication in human conversation.

The concerns extend to broader ecosystem damage, particularly impacts on India’s rich agricultural biodiversity and established community knowledge systems. Somik Banerjee, an expert on socio-economic and ecological balance, stressed that such technologies could “interfere” with vital seed diversity and traditional practices. “Every plant comes with its own biological equipment,” Banerjee noted, emphasizing that this is not merely a scientific risk but also threatens established agricultural and community systems.

Both experts called for a fundamental revisiting of Genetically Modified Organism (GMO) norms, arguing against any “exemption from norms” for genetically modified foods. This concern was particularly highlighted in the context of the rapid approval of “Rice Editte” by the Government of India. They advocated for transparency and “independent oversight” of research, free from conflicts of interest, asserting that “such powerful technologies demand a slow, thoughtful approach, adhering to the precautionary principle.”

Adding to the concerns, the presentation also touched upon emerging mRNA technologies, particularly those being developed for daily aerosol delivery. While acknowledging ongoing animal studies with plans for human trials, Dr. Kritika raised critical questions about the long-term effects of consuming and breathing gene-altering substances: “What will happen to the genes inside us, we know not.”

Further alarming findings were presented from a recent report by India’s National Institute of Mental Health and Neurosciences (NIMHANS) in Bengaluru. The study indicated a concerning rise in neurological complications among vaccinated individuals following COVID-19 vaccination, particularly with Covishield (AstraZeneca). While recognizing some neurological issues post-infection (3-4% in March-September 2020), the NIMHANS data revealed a significant spike, with 25% of neurological disorder cases in May-December 2021 occurring after vaccination – notably higher than the natural infection rate.

“Demyelination, indicating immune-mediated damage to the central nervous system, was a key finding,” the report noted, with 27 out of 29 studied cases linked to Covishield. The presentation referenced previous research by the Unity Against Organisms (UAO) on brain damage and clots, linking these neurological disorders to AstraZeneca/Covishield, recalling that the vaccine did not receive a license in the USA due to trial participants experiencing severe neurological symptoms like paralysis, and many European countries halted its use, especially for younger individuals, before the manufacturer eventually withdrew it from the market.

“We must not rush into adopting technologies with unknown long-term consequences. Transparent, independent research and rigorous risk assessment are paramount to protect our health, environment, and traditional knowledge,” Dr. Kritika emphasized.

The collective concerns from these experts, supported by mounting international scientific findings and research by groups like Public Consign to GM-Free India, underscore an urgent need for public discourse, comprehensive risk assessment, and a legislative re-evaluation of all novel genetic technologies. Advocacy groups continue to call for a moratorium until these risks are thoroughly understood and managed.

Citizen Advocates Demand Transparency and Independent Oversight in COVID-19 Vaccine Safety Research, Citing Flaws and Conflicts of Interest

A citizen advocacy group, UAE, today issued a strong call for immediate and transparent reforms in the scientific evaluation of COVID-19 vaccine safety in India. The group cited serious concerns over methodological flaws in current studies, alleged conflicts of interest within key research bodies, and a critical lack of robust long-term data on novel vaccine technologies.

Speaking on behalf of the group, a spokesperson emphasized the urgent need for a more rigorous and impartial approach to vaccine safety monitoring, particularly in light of recent public health discussions surrounding sudden cardiac events.

“Our trust in public health institutions hinges on their commitment to uncompromised scientific integrity and transparency,” stated the UAE spokesperson. “When studies are fundamentally flawed, and financial interests appear to influence research, public faith erodes. We demand access to original trial data, truly independent investigations, and a gold-standard Randomized Controlled Trial (RCT) with unvaccinated control groups to accurately understand the long-term safety profile of these new-technology vaccines.”

The group highlighted critical flaws in recent studies, particularly the Indian Council of Medical Research (ICMR)’s investigation into sudden cardiac deaths. UAE argues that studies comparing vaccinated individuals to other vaccinated individuals cannot accurately assess the association of vaccines with adverse events. “How can we ascertain vaccine-related associations from case-control studies where both control and cases groups are predominantly vaccinated?” the spokesperson questioned. “This methodology yields no meaningful data on causality.”

A central tenet of UAE’s demand is the need for independent oversight, free from financial ties. The group pointed to a perceived conflict of interest with the ICMR, alleging the organization’s involvement in vaccine development and receipt of royalties compromises its ability to conduct impartial safety investigations. In contrast, UAE suggested institutions like Nimhans, which they believe would be more credible due to their apparent lack of direct financial stake in vaccine manufacturing, should lead such crucial safety studies.

“We have consistently recommended the public release of original trial results for these new-technology vaccines, especially long-term data from unvaccinated control groups which we ourselves have worked on,” the spokesperson added. “Without such foundational data and robust, transparent RCTs like the ICMR study on long-term effects, it’s impossible to truly understand the safety profile.”

UAE also emphasized the critical importance of a robust system for monitoring Adverse Events Following Immunization (AEFI), stating, “Rare is not just rare. Unless you conduct a good study and establish a comprehensive monitoring system, you cannot definitively state whether an adverse event is rare or not. There must be good recording and investigation of adverse events.”

Further, UAE expressed concern over what they perceive as a media ‘cover-up’ or ‘propaganda,’ citing instances where media outlets attributed neurological disorders solely to COVID-19, allegedly omitting any mention of potential vaccine links in headlines. “This raises questions about whether what we’re seeing is science or propaganda,” the spokesperson noted.

The group also questioned the initial necessity of mass vaccination rollouts, suggesting that a significant portion of the population may have already developed natural antibodies prior to widespread vaccination, potentially rendering mass campaigns scientifically redundant for many. “While we cannot undo what has been done, in the future we must not panic to such an extent and take every report seriously,” the spokesperson urged.

UAE is a self-funded citizen advocacy group dedicated to promoting evidence-based public health policies, transparency in medical research, and accountability from health authorities. The group appeals to the public for support to expand its research and advocacy efforts.

About UAE: UAE is a citizen advocacy group committed to advocating for scientific rigor, transparency, and accountability in public health policy and medical research. The group focuses on ensuring that public health decisions are based on robust, unbiased evidence, free from conflicts of interest.

Also Watch :

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

ITBP Soldier’s Plea for Justice Sparks Nationwide Attention

National Duty, Personal Loss: ITBP Jawan Appeals for Fair Probe An emotional appeal by ITBP soldier Ramkishan Bharti, who...

“Thief, thief…” Eggs thrown at Mamata Banerjee as she marched in Kolkata

Chaos erupted in Kolkata, the capital of West Bengal, when eggs were thrown at a march led by...

Congress taunts BJP “Has the ‘pay money, get business’ scheme gone awry

The Congress party has taunted the government and demanded an explanation for the simultaneous removal of four officials...

Are Three Patti and Rummy games on your phone? Trouble!

If you're also interested in winning real cash by downloading NPP apps like Teen Patti, Rummy, or Poker...
news-1701

yakinjp

yakinjp

rtp yakinjp

yakinjp

yakinjp

yakin jp

yakinjp id

maujp

maujp

maujp

\

sabung ayam online

sabung ayam online

SLOT MAHJONG

sabung ayam online

invoice 00026

invoice 00027

invoice 00028

invoice 00029

invoice 00030

invoice 00031

invoice 00032

invoice 00033

invoice 00034

invoice 00035

invoice 00036

invoice 00037

invoice 00038

invoice 00039

invoice 00040

invoice 00041

invoice 00042

invoice 00043

invoice 00044

invoice 00045

invoice 00046

invoice 00047

invoice 00048

invoice 00049

invoice 00050

invoice 00051

invoice 00052

invoice 00053

invoice 00054

invoice 00055

article 2000021

article 2000022

article 2000023

article 2000024

article 2000025

article 2000026

article 2000027

article 2000028

article 2000029

article 2000030

article 2000031

article 2000032

article 2000033

article 2000034

article 2000035

article 2000036

article 2000037

article 2000038

article 2000039

article 2000040

article 2000041

article 2000042

article 2000043

article 2000044

article 2000045

article 2000046

article 2000047

article 2000048

article 2000049

article 2000050

article 2000051

article 2000052

article 2000053

article 2000054

article 2000055

article 2000056

article 2000057

article 2000058

article 2000059

article 2000060

article 2000061

article 2000062

article 2000063

article 2000064

article 2000065

article 2000066

article 2000067

article 2000068

article 2000069

article 2000070

article 2000071

article 2000072

article 2000073

article 2000074

article 2000075

article 2000076

article 2000077

article 2000078

article 2000079

article 2000080

pusdataru 00021

pusdataru 00022

pusdataru 00023

pusdataru 00024

pusdataru 00025

pusdataru 00026

pusdataru 00027

pusdataru 00028

pusdataru 00029

pusdataru 00030

pusdataru 00031

pusdataru 00032

pusdataru 00033

pusdataru 00034

pusdataru 00035

pusdataru 00036

pusdataru 00037

pusdataru 00038

pusdataru 00039

pusdataru 00040

pusdataru 00041

pusdataru 00042

pusdataru 00043

pusdataru 00044

pusdataru 00045

pusdataru 00046

pusdataru 00047

pusdataru 00048

pusdataru 00049

pusdataru 00050

pusdataru 00051

pusdataru 00052

pusdataru 00053

pusdataru 00054

pusdataru 00055

pusdataru 00056

pusdataru 00057

pusdataru 00058

pusdataru 00059

pusdataru 00060

article 00000031

article 00000032

article 00000033

article 00000034

article 00000035

article 00000036

article 00000037

article 00000038

article 00000039

article 00000040

article 00000041

article 00000042

article 00000043

article 00000044

article 00000045

article 00000046

article 00000047

article 00000048

article 00000049

article 00000050

article 00000051

article 00000052

article 00000053

article 00000054

article 00000055

article 00000056

article 00000057

article 00000058

article 00000059

article 00000060

article 00000061

article 00000062

article 00000063

article 00000064

article 00000065

article 00000066

article 00000067

article 00000068

article 00000069

article 00000070

article 00000071

article 00000072

article 00000073

article 00000074

article 00000075

article 00000076

article 00000077

article 00000078

article 00000079

article 00000080

pemohonan 000001

pemohonan 000002

pemohonan 000003

pemohonan 000004

pemohonan 000005

pemohonan 000006

pemohonan 000007

pemohonan 000008

pemohonan 000009

pemohonan 000010

pemohonan 000011

pemohonan 000012

pemohonan 000013

pemohonan 000014

pemohonan 000015

pemohonan 000016

pemohonan 000017

pemohonan 000018

pemohonan 000019

pemohonan 000020

pemohonan 000021

pemohonan 000022

pemohonan 000023

pemohonan 000024

pemohonan 000025

pemohonan 000026

pemohonan 000027

pemohonan 000028

pemohonan 000029

pemohonan 000030

artikel 000000081

artikel 000000082

artikel 000000083

artikel 000000084

artikel 000000085

artikel 000000086

artikel 000000087

artikel 000000088

artikel 000000089

artikel 000000090

artikel 000000091

artikel 000000092

artikel 000000093

artikel 000000094

artikel 000000095

artikel 000000096

artikel 000000097

artikel 000000098

artikel 000000099

artikel 000000100

artikel 000000101

artikel 000000102

artikel 000000103

artikel 000000104

artikel 000000105

artikel 000000106

artikel 000000107

artikel 000000108

artikel 000000109

artikel 000000110

artikel 000000111

artikel 000000112

artikel 000000113

artikel 000000114

artikel 000000115

artikel 000000116

artikel 000000117

artikel 000000118

artikel 000000119

artikel 000000120

pengadilan 000061

pengadilan 000062

pengadilan 000063

pengadilan 000064

pengadilan 000065

pengadilan 000066

pengadilan 000067

pengadilan 000068

pengadilan 000069

pengadilan 000070

pengadilan 000071

pengadilan 000072

pengadilan 000073

pengadilan 000074

pengadilan 000075

pengadilan 000076

pengadilan 000077

pengadilan 000078

pengadilan 000079

pengadilan 000080

pengadilan 000081

pengadilan 000082

pengadilan 000083

pengadilan 000084

pengadilan 000085

pengadilan 000086

pengadilan 000087

pengadilan 000088

pengadilan 000089

pengadilan 000090

perkara 0000066

perkara 0000067

perkara 0000068

perkara 0000069

perkara 0000070

perkara 0000071

perkara 0000072

perkara 0000073

perkara 0000074

perkara 0000075

perkara 0000076

perkara 0000077

perkara 0000078

perkara 0000079

perkara 0000080

perkara 0000081

perkara 0000082

perkara 0000083

perkara 0000084

perkara 0000085

perkara 0000086

perkara 0000087

perkara 0000088

perkara 0000089

perkara 0000090

article 0000021

article 0000022

article 0000023

article 0000024

article 0000025

article 0000026

article 0000027

article 0000028

article 0000029

article 0000030

article 0000031

article 0000032

article 0000033

article 0000034

article 0000035

article 0000036

article 0000037

article 0000038

article 0000039

article 0000040

article 0000041

article 0000042

article 0000043

article 0000044

article 0000045

article 0000046

article 0000047

article 0000048

article 0000049

article 0000050

article 0000051

article 0000052

article 0000053

article 0000054

article 0000055

article 0000056

article 0000057

article 0000058

article 0000059

article 0000060

article 0000061

article 0000062

article 0000063

article 0000064

article 0000065

article 0000066

article 0000067

article 0000068

article 0000069

article 0000070

article 3000031

article 3000032

article 3000033

article 3000034

article 3000035

article 3000036

article 3000037

article 3000038

article 3000039

article 3000040

article 3000041

article 3000042

article 3000043

article 3000044

article 3000045

article 3000046

article 3000047

article 3000048

article 3000049

article 3000050

article 3000051

article 3000052

article 3000053

article 3000054

article 3000055

article 3000056

article 3000057

article 3000058

article 3000059

article 3000060

news-1701
content-1701

artikel 0000106

artikel 0000107

artikel 0000108

artikel 0000109

artikel 0000110

artikel 0000111

artikel 0000112

artikel 0000113

artikel 0000114

artikel 0000115

artikel 0000116

artikel 0000117

artikel 0000118

artikel 0000119

artikel 0000120

artikel 0000121

artikel 0000122

artikel 0000123

artikel 0000124

artikel 0000125

artikel 0000126

artikel 0000127

artikel 0000128

artikel 0000129

artikel 0000130

artikel 0000131

artikel 0000132

artikel 0000133

artikel 0000134

artikel 0000135

pengadilan 000086

pengadilan 000087

pengadilan 000088

pengadilan 000089

pengadilan 000090

pengadilan 000091

pengadilan 000092

pengadilan 000093

pengadilan 000094

pengadilan 000095

pengadilan 000096

pengadilan 000097

pengadilan 000098

pengadilan 000099

pengadilan 000100

pengadilan 000101

pengadilan 000102

pengadilan 000103

pengadilan 000104

pengadilan 000105

article 3000061

article 3000062

article 3000063

article 3000064

article 3000065

article 3000066

article 3000067

article 3000068

article 3000069

article 3000070

article 3000071

article 3000072

article 3000073

article 3000074

article 3000075

article 3000076

article 3000077

article 3000078

article 3000079

article 3000080

article 3000081

article 3000082

article 3000083

article 3000084

article 3000085

article 3000086

article 3000087

article 3000088

article 3000089

article 3000090

article 3000091

article 3000092

article 3000093

article 3000094

article 3000095

article 3000096

article 3000097

article 3000098

article 3000099

article 3000100

article 3000101

article 3000102

article 3000103

article 3000104

article 3000105

article 3000106

article 3000107

article 3000108

article 3000109

article 3000110

article 3000111

article 3000112

article 3000113

article 3000114

article 3000115

article 3000116

article 3000117

article 3000118

article 3000119

article 3000120

article 2000081

article 2000082

article 2000083

article 2000084

article 2000085

article 2000086

article 2000087

article 2000088

article 2000089

article 2000090

article 2000091

article 2000092

article 2000093

article 2000094

article 2000095

article 2000096

article 2000097

article 2000098

article 2000099

article 2000100

article 2000101

article 2000102

article 2000103

article 2000104

article 2000105

article 2000106

article 2000107

article 2000108

article 2000109

article 2000110

invoice 00055

invoice 00056

invoice 00057

invoice 00058

invoice 00059

invoice 00060

invoice 00061

invoice 00062

invoice 00063

invoice 00064

invoice 00065

invoice 00066

invoice 00067

invoice 00068

invoice 00069

invoice 00070

invoice 00071

invoice 00072

invoice 00073

invoice 00074

invoice 00075

invoice 00076

invoice 00077

invoice 00078

invoice 00079

invoice 00080

invoice 00081

invoice 00082

invoice 00083

invoice 00084

invoice 00085

invoice 00086

article 238000401

article 238000402

article 238000403

article 238000404

article 238000405

article 238000406

article 238000407

article 238000408

article 238000409

article 238000410

article 238000411

article 238000412

article 238000413

article 238000414

article 238000415

article 238000416

article 238000417

article 238000418

article 238000419

article 238000420

article 238000421

article 238000422

article 238000423

article 238000424

article 238000425

article 238000426

article 238000427

article 238000428

article 238000429

article 238000430

article 238000431

article 238000432

article 238000433

article 238000434

article 238000435

article 238000436

article 238000437

article 238000438

article 238000439

article 238000440

article 238000441

article 238000442

article 238000443

article 238000444

article 238000445

article 238000446

article 238000447

article 238000448

article 238000449

article 238000450

article 238000451

article 238000452

article 238000453

article 238000454

article 238000455

article 238000456

article 238000457

article 238000458

article 238000459

article 238000460

artikel 0000136

artikel 0000137

artikel 0000138

artikel 0000139

artikel 0000140

artikel 0000141

artikel 0000142

artikel 0000143

artikel 0000144

artikel 0000145

artikel 000000121

artikel 000000122

artikel 000000123

artikel 000000124

artikel 000000125

artikel 000000126

artikel 000000127

artikel 000000128

artikel 000000129

artikel 000000130

artikel 000000131

artikel 000000132

artikel 000000133

artikel 000000134

artikel 000000135

artikel 000000136

artikel 000000137

artikel 000000138

artikel 000000139

artikel 000000140

artikel 000000141

artikel 000000142

artikel 000000143

artikel 000000144

artikel 000000145

artikel 000000146

artikel 000000147

artikel 000000148

artikel 000000149

artikel 000000150

article 0000091

article 0000092

article 0000093

article 0000094

article 0000095

article 0000096

article 0000097

article 0000098

article 0000099

article 0000100

article 0000101

article 0000102

article 0000103

article 0000104

article 0000105

article 0000106

article 0000107

article 0000108

article 0000109

article 0000110

article 0000111

article 0000112

article 0000113

article 0000114

article 0000115

article 0000116

article 0000117

article 0000118

article 0000119

article 0000120

content-1701